To continue reading this content, please enable JavaScript in your browser settings and refresh this page. For American men, prostate cancer is the most common cancer ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about understanding Gleason Score and prostate cancer risk. As part of its Speaking ...

The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a ...

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment intensification can meaningfully improve survival for patients with ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

“For localised prostate cancer, treatment options include surgery or radiotherapy. Both give equivalent cure rates,” Dr Komen ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at EPFL, and Eneda Toska at Johns Hopkins University have identified the enzyme ...

A large national and international study has identified dozens of blood proteins linked to prostate cancer risk, some shared across populations, some unique to specific groups. Published in Nature ...

Cancer survival in the U.S. has climbed to 70%, reflecting major advances in treatment, early detection and personalized care ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...